Children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia now have a new reason to pay attention.

Fate Therapeutics (FATE) pivots to autoimmune CAR T-cell therapies, with FT819 advancing toward a registrational lupus ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

Scientists from the University of Southern California found that in animal trials, the new immune cells were able to fight ...

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its partner company with Aditum Bio, ...

TheFly reported on June 3 that UBS increased its price target on LEGN to $49 from $31 while reiterating a Buy rating on the ...

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...

Almost a third of patients with aggressive lymphoma remained cancer free 10 years after treatment with CAR T-cell therapy. The long-term data indicate that CD19-directed CAR T-cell therapy may cure ...

New data presented at the EULAR Congress 2026 suggest CAR-T therapies may deliver sustained remission across multiple RMDs.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster presentations for CT0596 (an allogeneic CAR T-cell ...